Dear Madame/Sir,

In our manuscript submitted, the results presented are based on the research performed at Maria Sklodowska-Curie Oncology Center in Białystok on 5 participants, and they include:

- laboratory criteria (e.g. cut-off for SARS CoV-2 IgG on level 0,2 AU/ml), allowing the find out healthy and unvaccinated convalescents who passed SARS-CoV-2 asymptomatically, which had diagnostic and therapeutic implications for further oncology treatment.
- a proposal for a method of assessing immunity after SARS CoV-2 exposition and after COVID-19 planned vaccination in prevention to oncology treatment using measurement IgG-specific and S-RBD.

The work sent by us is a voice in the discussion for a need to introduce a third and additional dose of vaccine at a particular proper time to prevent SARS CoV-2 infection, especially for people elderly and immunosuppressive. In that population, functional immunodeficiency is a risk factor for developing clinically severe infections. Counting on a substantive and kind evaluation of our work, we express our respect,

Piotr Kosiorek MD, PhD